Clinical Trials
39 trialsA Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
FT576 in Subjects With Multiple Myeloma
Fate Therapeutics
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Thomas Jefferson University
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Thomas Jefferson University
BEB-2
Insel Gruppe AG, University Hospital Bern
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Columbia University
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Corewell Health West
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
Washington University School of Medicine
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Hoosier Cancer Research Network
OPTIMAL
Oxford University Hospitals NHS Trust
Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma
Shengjing Hospital
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
BVD
Intergroupe Francophone du Myelome
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Medical College of Wisconsin
BPV
University Hospital Heidelberg
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Columbia University
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
NYU Langone Health
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
Weill Medical College of Cornell University
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
University of California, Davis
BVRD
Loyola University
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
Azienda Ospedaliera di Bolzano
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
NYU Langone Health
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
University of Louisville
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
University of Pittsburgh
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
SCRI Development Innovations, LLC
BRd
Cantonal Hospital of St. Gallen
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
PETHEMA Foundation
BBD
Austrian Forum Against Cancer
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
Gruppo Italiano Studio Linfomi
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
University of Leipzig